labarai
A halin da ake ciki na tsadar farashi na maganin cutar kansa, yawancin FDA da EMA sun yarda da kwayoyi masu cutar kansa sun shiga kasuwa bisa la'akari da ƙarshen ƙarshen, ba tare da shaidar fa'ida akan rayuwar gaba ɗaya ko ƙimar rayuwa ba, kamar yadda rahoton binciken asibiti ke nazarin yarda da kwayar cutar kansa tsakanin 2008-2013: Bincike mai fa'ida game da Magungunan Cancer.
Ko da yake ingancin sabo ciwon daji Magungunan suna haɓaka kaɗan kaɗan, farashin yana tashi sama kamar ba a taɓa gani ba. Ana ci gaba da kiraye-kirayen daukar matakan da suka dace ga hukumomin da suka dace da su daga matakin kimiyya na amincewa da sabbin magungunan cutar kansa wadanda a halin yanzu suna iya nuna wasu hujjoji na inganci da shiga kasuwa ba tare da wata hujja ta hakika da cewa maganin zai amfanar da mara lafiya ta hanyar ingantawa ba. ma'aunin rayuwa da ingancin rayuwa. Akwai sabbin hanyoyin ka'idoji waɗanda FDA ta ƙirƙira, kamar naɗawar nasara, saurin tafiya ko hanyoyin haɓaka, don samun magunguna don barazanar rayuwa ko cututtukan da ba kasafai ba zuwa kasuwa cikin sauri dangane da madaidaitan wuraren ƙarshe; amma akwai bincike na gaba da aka wajabta don nuna tabbacin inganci. Wani rahoto na ofishin lissafin gwamnati (GAO) na 2009 ya soki FDA ta Amurka saboda gaza aiwatar da alkawurran nazarin tallace-tallacen tallace-tallace don magungunan da aka amince da su akan ƙarshen ƙarshen (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61932 -2/ cikakken rubutu). Don haka a yau, bisa nazarin magungunan da aka yarda da su a cikin shekaru goma da suka gabata, ana samun karuwar damuwa game da sanya tsada, magunguna masu guba a cikin kayan aikin likita waɗanda ba su inganta rayuwa gaba ɗaya ba.
Abincin da Zai Ci Bayan Bayanan Ciwon Cutar Kansa!
Babu cutar kansa guda biyu iri daya. Wuce ka'idojin abinci mai gina jiki na kowa don kowa kuma yanke hukunci na musamman game da abinci da kari tare da ƙarfin gwiwa.
Amfanin Tsira na Magungunan Cancer da Aka Amince
Akwai irin waɗannan karatun guda biyu, ɗayan yana kallon ƙwayoyin da aka yarda tsakanin 2008-2012 na US FDA (Kim da Prasad, JAMA Intern Med., 2015) kuma tsakanin 2009-2013 na EMA (hukumar kula da lafiya ta Turai) (Davis C et al, BMJ., 2017), duka nuna rubutu a sama. Binciken na FDA ya ba da rahoton cewa 36 na 54 (67%) na yarda da maganin cutar kansa sun dogara ne da ƙarshen sakamako kamar rage girman ƙari ko kwanakin da mai haƙuri ya kasance ba shi da cuta (ci gaban rayuwa kyauta). Bayan shekaru 4.4 na bin diddigin wadannan kwayoyi masu dauke da cutar ta FDA, 5 ne kawai daga cikin 36 (14%) da aka amince da su suka nuna ingantaccen rayuwa, yayin da 31 (86%) daga cikin wadannan suka gaza ko kuma basu da wani bayani game da tasirin rayuwa. Don nazarin EMA na magungunan kansar da aka yarda tsakanin 2009-2013, akwai magunguna 48 da aka yarda su je kasuwa don alamun cutar kansa 68 kuma kawai 35 (51%) daga cikin waɗannan sun nuna ci gaba a rayuwa ko ƙimar rayuwa. An yi amfani da amfanin rayuwa da mahimmancin asibiti na waɗannan kwayoyi ta amfani da sikelin ESMO-MCBS (Europeanungiyar Turai don Magungunan Magungunan Magungunan Kiwon Lafiyar Magunguna), wanda shine daidaitaccen tsarin da aka yi amfani da shi don kimanta girman darajar asibiti da ingancin magungunan cutar kansa. Abinda yafi damun shine duk da rashin ingancin ingancin da yawa daga cikin wadannan magunguna da aka yarda dasu a kasuwa, farashin su na ci gaba da kasancewa mai girman gaske.
Misali na musamman game da wannan shi ne magani Regorafenib wanda aka tsara don magance ƙarshen matakan kansar kansa, kansar kansar hanji ko dubura wanda shine na uku mafi yawan sankara a cikin Amurka (American Cancer Society). An ba Regorafenib darajar 1 ta kayan aikin ESMO-MCBS wanda ke nufin cewa kusan ba shi da fa'idodi na asibiti ko kuma fa'idodi ga rayuwar mutum (Davis C et al, BMJ., 2017). Bugu da ƙari, wannan magani ba shi da tasiri sosai tare da tsada mai tsada da ƙarancin asibiti (Cho SK et al, Ciwon Kansar Launin Lafiyar., 2018). Duk da haka, an ƙaddamar da shi a cikin kasuwa azaman magani na 'nasara' don ƙarshen matakin kansar kai tsaye.
Mahimmanci, wannan shafin yanar gizon an yi niyya ne don sa marasa lafiya da ƙaunatattun su san ainihin ainihin gaskiyar ciwon daji kwayoyi da kuma roƙon su don yin nazari mai fa'ida mai tsada, la'akari da duk zaɓuɓɓukan maganin su kuma yin zaɓi mai ma'ana maimakon bin makantar da kasuwar yanzu ta ba da shawarar sabbin zaɓuɓɓuka masu tsada.
Abincin da kuke ci kuma wanne kari kuke ɗauka shine yanke shawara. Ya kamata shawararku ta haɗa da la'akari da maye gurbi na ciwon daji, wanda cutar kansa, jiyya da ci gaba da gudana, duk wani rashin lafiyan, bayanin salon rayuwa, nauyi, tsayi da halaye.
Tsarin abinci mai gina jiki don cutar kansa daga addon baya dogara ne akan binciken intanet. Yana sarrafa muku yanke shawara ta atomatik dangane da kimiyyar kwayoyin da masana kimiyya da injiniyoyin software suka aiwatar. Ba tare da la’akari da ko kuna kula da fahimtar hanyoyin hanyoyin kwayoyin halittar biochemical ko a'a - don shirin abinci mai gina jiki don cutar kansa wanda ake buƙatar fahimta.
Fara NOW tare da shirin abinci mai gina jiki ta hanyar amsa tambayoyi kan sunan cutar kansa, maye gurbi, jiyya mai gudana da kari, duk wani rashin lafiyan, halaye, salon rayuwa, ƙungiyar shekaru da jinsi.
Keɓaɓɓen Abinci don Ciwon daji!
Ciwon daji yana canzawa da lokaci. Keɓancewa da canza abincin ku dangane da alamun cutar kansa, jiyya, salon rayuwa, abubuwan da ake so abinci, alerji da sauran dalilai.
Marasa lafiya masu cutar kansa sau da yawa dole su magance daban-daban illar illa na chemotherapy wanda ke shafar ingancin rayuwarsu da kuma neman wasu hanyoyin magance cutar kansa. Shan da madaidaicin abinci mai gina jiki da kari bisa la'akari na kimiyya (gujewa zato da zabin bazata) shine mafi kyawun maganin halitta don cutar kansa da cututtukan da suka shafi jiyya.